Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review

2009/03/17 by J J Luime, Jolanda J. Luime, E M Colin +5 · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #Rheumatoid Arthritis Research and Therapies #Skin and Cellular Biology Research

paper · doi:10.1136/ard.2008.103283

openalex publication_date 2009/03/17 · crossref created 2009/03/17 · crossref issued 2010/02/01 · crossref published 2010/02/01 · crossref published-print 2010/02/01 · crossref deposited 2025/01/19 · openalex created_date 2025/10/10 · crossref indexed 2026/03/09 · openalex updated_date 2026/08/01

Citations

• Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
• The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

Cited by

• Rheumatoid arthritis [wikipedia]